96 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22761 | Identified PIK3CA status | Ahmad Hussein Awada | Breast | Novartis | SOLAR-1 CBYL719C2301 | Trial closed | A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment CBYL719C2301 (SOLAR-1) | ahmad.awada@hubruxelles.be | 3 | 3 | |
| 23023 | RECIST v1.1 | Philippe Aftimos | Multiple | Synthon Biopharmaceuticals | SYD985.004 | Trial closed for recruitment | A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22706 | ER+/HER2+. cT1-3. N0-1. >1 cm. Neoadjuvant. Age >65 years old | Andrea Gombos | Breast | IBCSG | TOUCH | Trial closed | Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer (IBCSG 55-17 / TOUCH) | accueil.oncologie@hubruxelles.be | 2 | 2 | |
| 29331 | Andrea Gombos | Breast | AstraZeneca | TROPION-Breast01 | Trial closed for recruitment | A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy | accueil.oncologie@hubruxelles.be | 3 | 3 | ||
| 29674 | Michail Ignatiadis | Breast | AstraZeneca | TROPION-Breast03 | Trial open for recruitment | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) | michail.ignatiadis@hubruxelles.be | 3 | 3 | ||
| 22665 | HER2 positive/ RECIST 1.1/ After HER2 targeting treatment | Philippe Aftimos | Breast | Synthon Biopharmaceuticals | TULIP | Trial closed | A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer / TULIP | philippe.aftimos@hubruxelles.be | 3 | 3 | |
| 22670 | Progressive. At least 1 line of athracycline and/or taxane | Daphné t'Kint de Roodenbeke | Breast | AstraZeneca | VIOLETTE | Trial closed | A Phase II, Open Label, randomized, Multi-center Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR-Related Genes (including BRCA 1/2) (VIOLETTE) | daphne.tkint@hubruxelles.be | 2 | 2 | |
| 22752 | Triple negative. Metastatic. 1st Line | Andrea Gombos | Breast | Roche | WO29522 | Trial closed | A Phase III, MULTICENTER, RANDOMIZED, placebo-controlled Study OF MPDL3280A (Anti-PD-L1 Antibody) IN COMBINATION WITH NAB-PACLITAXEL COMPARED with placebo with NAB-PACLITAXEL for PATIENTS WITH previously UNtreated metastatic TRIPLE-NEGATIVE BREAST CANCER | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22686 | HER2+. Early breast cancer | Evandro De Azambuja | Breast | Roche | WO40324 | Trial closed for recruitment | A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in combination with chemotherapy in patients with HER2-positive early breast cancer | 3 | 3 | ||
| 22731 | Triple-negative breast cancer | Philippe Aftimos | Breast | Zenith Epigenetics Ltd. | ZEN003694-004 | Trial closed | A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 22611 | *HER2+ invasive carcinoma of the breast *progressive disease with at least 2 non-bone 'target' metastatic lesions *biopsy of a metastatic site before inclusion |
Patrick Flamen | Breast | Institut Jules Bordet | ZEPHIR | Trial closed for recruitment | A phase II prospective imaging study evaluating the utility of pretreatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast cancer unlikely to benefit from a novel anti-HER2 therapy : T-DM1 | patrick.flamen@hubruxelles.be | 2 | 2 | |
| 29237 | Michail Ignatiadis | Breast | GSK | ZEST | Trial closed for recruitment | A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy | michail.ignatiadis@hubruxelles.be | 3 | 3 |